Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers track lassa virus spread in mali to aid future prevention

NCT ID NCT03783143

Knowledge-focused Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This completed study looked at how many people in southern Mali have ever been infected with Lassa virus and how many new infections occur each year. Over 8,500 participants aged 6 months to 99 years gave blood samples and answered questions about fevers and mouse exposure. The goal is to better understand the virus to improve diagnosis and prevention.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help researchers better understand Lassa virus spread and develop better diagnostic tools and prevention strategies.
What could go wrong
This is an observational study, not a treatment trial. It only measures infection rates and cannot directly improve health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

8,524 people

The number who actually took part.

Started

Dec 2020

Finished

Jul 2024

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Individuals will be randomly identified from village census lists, and a member of the study team will contact the individual by phone or in person about potential participation in the study. In accordance with cultural practices, the individual s entire household will be invited to participate

Ages

6 months to 110 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: 1. Age greater than or equal to 6 months to 99 years. 2. Resident of one of the study sites for at least 3 months. 3. Able to provide informed consent. 4. Agrees to allow storage of samples for future research. Additional inclusion criteria for the cross-sectional study (study 1): 1\. No plans to relocate before the study end date. Additional inclusion criteria for the clinic-based study (study 2): 1. Has fever (temperature greater than or equal to 38 degree celcius), or has had antecedent of fever for at least 2 consecutive days at the time of screening. 2. One or more of the following: 1. Excluded typhoid fever and and has at least 1 of the following symptoms: chest pain, sore throat, headache, muscle pain,vomiting, and diarrhea. 2. Shows bleeding or facial edema. 3. Does not respond to anti-malarials or antibiotics after 2 days of treatment. 4. Had contact with a confirmed LF case within the last 3 weeks. EXCLUSION CRITERIA: General exclusion criteria: 1. Any condition that, in the opinion of the investigator, contraindicates participation in this study, including conditions that could hinder compliance or that could place participants or study staff at increased risk. 2. Pregnancy. Additional exclusion criteria for the clinic-based study (study 2): 1\. Signs or symptoms of fever-associated conditions other than LF, such as urinary tract infection, or any other infection that may cause fever. Co-enrollment guidelines: Participants may be co-enrolled in other studies; however, study staff should be notified of co-enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lassa virus infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fever HIV Seropositivity Lassa fever lassa virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lassa virus infection

Contacts and locations

Locations

  • Icer/Mrtc/Fmos/Usttb

    Bamako, Mali